AI-generated analysis. Always verify with the original filing.
Trinity Biotech plc announced successful clinical results for its enhanced EpiCapture™ prostate cancer test, achieving 85% AUC accuracy in a study of approximately 750 ethnically diverse patient samples using machine learning and patient ethnicity data. The company plans to commercialize the test as a Laboratory Developed Test through its New York reference laboratory, marking its entry into precision oncology diagnostics.